

A study evaluating the effect of itraconazole on DNL343 in healthy participants

Submission date 05/03/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 14/03/2024	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 31/01/2025	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

This is a drug-drug interaction (DDI) study designed to evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose of DNL343 in the absence and presence of itraconazole (ITZ) with a planned enrollment of 16 healthy participants. A DDI study is run to see how two drugs interact in the body; evaluating PK is figuring out how participants' bodies handle a drug or drugs in combination.

Who can participate?

Healthy volunteers aged 18 - 55 years

What does the study involve?

The total duration of each participant's involvement in the study will be approximately 73 days from screening through follow-up.

What are the possible benefits and risks of participating?

Healthy participants in this study will not receive any health benefit from participating in the study. The risks of DNL343 treatment are based on extensive evaluation in nonclinical studies (ie, animal studies and studies done with cells in a petri dish) and evaluation in clinical studies in healthy participants to characterize the safety profile. The potential risks of participation are primarily those associated with adverse reactions to the study interventions (DNL343 and ITZ).

Where is the study run from?

Denali Therapeutics Inc. (USA)

When is the study starting and how long is it expected to run for?

December 2021 to July 2022

Who is funding the study?

Denali Therapeutics Inc. (USA)

Who is the main contact?

Clinical Trials Disclosures Group at Denali Therapeutics, clinical-trials-disclosures@dnli.com

Contact information

Type(s)

Principal Investigator

Contact name

Dr Helen Philpott

Contact details

Simbec-Orion Clinical Pharmacology
Merthyr Tydfil Industrial Park
Cardiff Road
Merthyr Tydfil
United Kingdom
CF48 4DR
+44 (0)1443694315
helen.philpott@simbecorion.com

Type(s)

Public, Scientific

Contact name

Ms Gabrielle Brill

Contact details

Simbec-Orion Clinical Pharmacology
Merthyr Tydfil Industrial Park
Cardiff Road
Merthyr Tydfil
United Kingdom
CF48 4DR
+44 (0)1443 694319
gabrielle.brill@simbecorion.com

Type(s)

Public

Contact name

Dr Clinical Trials Disclosures Group -

Contact details

Denali Therapeutics
-
United States of America
-
None provided
clinical-trials-disclosures@dnli.com

Additional identifiers

EudraCT/CTIS number

2021-006382-37

IRAS number

310753

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

DNLI-F-0005, IRAS 310753

Study information

Scientific Title

A fixed-sequence, drug-drug interaction study evaluating the effect of the cytochrome P450 3A inhibitor itraconazole on DNL343 in healthy participants

Study objectives

To evaluate the pharmacokinetics (PK) safety, and tolerability of a single dose of DNL343 in the absence and presence of itraconazole.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 18/01/2022, Wales Research Ethics Committee 2 (Health and Care Research Wales Castlebridge 4 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0) 2922941119; Wales.REC2@wales.nhs.uk), ref: 22/WA/0009

Study design

Phase 1 single-center open-label fixed-sequence drug-drug interaction study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Other

Study type(s)

Other

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

Single oral dose of DNL343 without and with repeating oral doses of itraconazole.

The total duration of each participant's involvement in the study will be approximately 73 days from screening through follow-up.

Intervention Type

Drug

Pharmaceutical study type(s)

Pharmacokinetic

Phase

Phase I

Drug/device/biological/vaccine name(s)

DNL343; itraconazole

Primary outcome measure

DNL343 PK parameters, as measured by laboratory analysis of plasma concentrations from blood samples, including, but not limited to, the following:

1. Maximum concentration (C_{max})
2. Area under the concentration-time curve from time zero to infinity (AUC_∞)
3. Area under the concentration-time curve from time zero to time of last measurable concentration (AUC_{last})

[Timeframe: Multiple timepoints over 45 days]

Secondary outcome measures

Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs) as reported by the participant (or, when appropriate, by a caregiver, a surrogate, or the participant's legally authorized representative)

[Timeframe: Continuously over 45 days]

Overall study start date

16/12/2021

Completion date

25/07/2022

Eligibility

Key inclusion criteria

1. Healthy male participants and healthy female participants of non-childbearing potential
2. Aged ≥18 to ≤55 years
3. Body mass index (BMI) of ≥18.5 to ≤30 kg/m²
4. Body weight of ≥50 kg

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Upper age limit

55 Years

Sex

Both

Target number of participants

16

Total final enrolment

24

Key exclusion criteria

1. History of clinically significant endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders
2. History of malignancy, except fully resected basal cell carcinoma
3. History of clinically significant neurological or psychiatric diseases
4. History of serious adverse reaction or serious hypersensitivity to any drug, or history of allergy to any component of the DNL343 or itraconazole products
5. Are pregnant (ie, positive pregnancy test) or breastfeeding

Date of first enrolment

09/02/2022

Date of final enrolment

18/05/2022

Locations

Countries of recruitment

United Kingdom

Wales

Study participating centre

Simbec-Orion Clinical Pharmacology (AKA Simbec Research Ltd)

Merthyr Tydfil Industrial Park

Cardiff Road

Merthyr Tydfil
United Kingdom
CF48 4DR

Sponsor information

Organisation

Denali Therapeutics (United States)

Sponsor details

161 Oyster Point Boulevard
South San Francisco
United States of America
94080
+1 (0)650 866 8548
clinical-trials@dnli.com

Sponsor type

Industry

Website

<https://www.denalitherapeutics.com/>

ROR

<https://ror.org/00pprn321>

Funder(s)

Funder type

Industry

Funder Name

Denali Therapeutics

Alternative Name(s)

DENALI, Denali Therapeutics Inc.

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

Results and Publications

Publication and dissemination plan

We intend to request an update to the record with a results summary by the time the results deferral lapses (25Jan2025).

Intention to publish date

25/01/2025

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		21/07/2023	31/01/2025	No	No